Investment Firm BETS MILLIONS on Rare Disease Stock! +40% Growth NOW!
Did you know one major investment firm just poured millions into a biotech company, making it one of their top holdings? Palo Alto Investors LP recently bought over 41,000 additional shares of PTC Therapeutics for an estimated $3 million, significantly increasing their stake. This bold move brings their total investment in the rare disease specialist to nearly $69 million, representing almost 10 percent of their managed assets. Furthermore, PTC Therapeutics has been a standout performer, surging nearly 40 percent over the past year and outperforming the S&P 500. This indicates a strong conviction in the company's innovative treatments for conditions like Duchenne muscular dystrophy. To stay ahead of these high-stakes investment plays, be sure to subscribe to our channel for more exclusive insights!
Tags/Hashtags: #insm #fold #acad #bmrn
Leave a Reply